Диссертация (1141395), страница 21
Текст из файла (страница 21)
Investigation of nanocapsules stabilization by amorphousexcipients during freeze-drying and storage / W. Abdelwahed, G. Degobert, H.Fessi // European Journal of Pharmaceutics and Biopharmaceutics. – 2006. – Vol.2. – P.87-94.89. Alsenz, J. High throughput solubility measurement in drug discovery anddevelopment / J. Alsenz, M. Kansy // Adv Drug Deliv Rev. – 2007. – Vol.
59. – P.546-567.90. Anhorn, M.G. Freeze drying of human serum albumin (HSA) nanoparticleswith different excipients / M.G. Anhorn, H. Hanns-Christian Mahler, K. Langer //International Journal of Pharmaceutics. – 2008. – Vol. 1–2. – P. 162-169.91. Arun, K. Techniques to improve the absorption of poorly soluble drugs / K.Arun, C.J. Babu, P. Laksmaiah [et al.] // International journal of research inpharmacy and chemistry.
– 2012. – Vol. 2. – № 2. – P. 41-54.92. Baheti, A. Excipients used in lyophilization of small molecules / A. Baheti, L.Kumar, A.K. Bansal // J. Excipients and Food Chem. – 2010. – Vol. 1. – № 1. – P.41-54.93. Benito-Gallo, P. Smart Lipid-Based Drug Delivery Systems / P. Benito-Gallo,P. Gershkovich, M. Marlow [et al.] // Smart Pharmaceutical Nanocarriers. – 2016.– Vol. 1 – P.
309-371.94. Bennett, A. Pharmaceuticals and fine chemicals: Filtration and separation inthe diverse fine chemical sectors / A. Bennett // Filtration + Separation. – 2013. –Vol. 50. – № 6. – P. 30-33.12795. Bharali, D.J. Nanoparticles and cancer therapy: A concise review withemphasis on dendrimers / D.J. Bharali, M. Khalil, M. Gurbuz [et al.] //International Journal of Nanomedicine. – 2009. – Vol. 4. – P. 1-7.96. Blanco, E. Multifunctional micellar nanomedicine for cancer therapy / E.Blanco, C.W. Kessinger, B.D.
Sumer, J. Gao // Experimental Biology andMedicine (Maywood). – 2009. – Vol. 234. – № 2. – P.123-131.97. Brewster, M.E. Cyclodextrins as pharmaceutical solubilizers / M.E. Brewster //Advanced Drug Delivery Reviews. – 2007. – Vol. 59. – P. 645-666.98. Carvalho Junior, A.D. Preparation and cytotoxicity of cisplatin-containingliposomes / A.D.
Carvalho Junior, F.P. Vieira, V.J. De Melo [et al.] // BrazilianJournal of Medical and Biological Research. – 2007. – Vol. 40. – P. 1149–1157.99. Catapano, C.G. Accuracy of automated instruments used in the pharmaceuticalindustry for integrity testing sterilizing filters / C.G. Catapano // J. Pharm.
Sci.Techol. – 2003. – Vol. 4. – P. 277-286.100. Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) inPatients With Platinum-resistant Ovarian Cancer (CHIP). [Электронный ресурс]Режим доступа:http://clinicaltrials.gov/ct2/show/NCT01639885?term=DMSO&rank=25.обращения: 25.10.13)(дата101. Cross-section view of the structures that can be formed by phospholipids inaqueous solutions.
[Электронный ресурс] Режим доступа:https://en.wikipedia.org/wiki/Micelle#/media/File:Phospholipids_aqueous_solution_structures.svg. (дата обращения: 12.12.16)102. Giri, T.K. Prospects of pharmaceuticals and biopharmaceuticals loadedmicroparticles prepared by double emulsion technique for controlled delivery /T.K. Giri, C.
Choudhary, Ajazuddin [et al.] // Saudi Pharmaceutical Journal. –2013. – Vol. 2. – P.125-141.103. Hardwicka, L.M. A proposed rationale and test methodology forestablishment of acceptance criteria for vacuum integrity testing of pharmaceuticalfreeze dryers / L.M.
Hardwicka, S.L. Naila, J. Jarmana [et al.] // European Journalof Pharmaceutics and Biopharmaceutics. – 2013. – Vol. 2. – P.236-239.128104. Huh, K.M. A new hydrotropic block copolymer micelle system foraqueous solubilization of paclitaxel / K.M. Huh, H.S. Min, S.C. Lee [et al.] //Journal of Controlled Release. – 2008.
– Vol. 126. – P.122-129.105. Huober, J. A multicentric observational trial of pegylated liposomaldoxorubicin for metastatic breast cancer / J. Huober, W. Fett, A. Nusch [et al.] //BMC Cancer. – 2010. – Vol. 7. – P.10-12.106. Image of a liposome. [Электронный ресурс]Режим доступа:https://ru.wikipedia.org/wiki/%D0%9B%D0%B8%D0%BF%D0%BE%D1%81%D0%BE%D0%BC%D0%B0#/media/File:Liposoom.jpg.(датаобращения:12.12.16)107. Kawakami, K.
Solubilization behavior of a poorly soluble drug undercombined use of surfactants and cosolvents / K. Kawakami, N. Oda, K. Miyoshi[et al.] // European journal of pharmaceutical sciences. – 2006. – Vol. 28. – P. 714.108. Lantsova, A. Biopharmaceutical study of nanostructured formulation of theanticancer drug derivative of nitrosoalkylurea lysomustine / A. Lantsova, E.Kotova, K. Sanarova [et al.] // Journal of Drug Delivery Science and Technology.– 2012. – Vol. 22. – № 6. – P.469-472.109. Levy, R.V.
Types of filtration / R.V. Levy, M.W. Jornitz // Adv. Biochem.Eng. Biotechnol. – 2006. – Vol. 98. – P. 1-26.110. Li, L.B. Preparation and characterization of Pluronic/TPGS mixed micellesfor solubilization of camptothecin / L.B. Li, G. Zhai, Y. Gao // Colloids andSurfaces B: Biointerfaces. – 2008. – Vol. 64. – P. 194-199.111.
Meyer, B.K. Impact of tubing material on the failure of product-specificbubble points of sterilizing-grade filters / B.K. Meyer, D. Vargas // J. Pharm. Sci.Techol. – 2006. – Vol. 4. – P. 248-253.112. Morral-Ruíz, G. Polyurethane and polyurea nanoparticles based onpolyoxyethylene castor oil derivative surfactant suitable for endovascularapplications / G. Morral-Ruíz, P.
Melgar-Lesmes, García [et al.] // Internationaljournal of pharmaceutics. – 2014. – Vol. 461. – № 1. – P. 1-13.129113. Nock, C.J. A phase I study of rebeccamycin analog in combinationwith oxaliplatin in patients with refractory solid tumors / C.J. Nock, J.M. Brell,J.A. Bokar [et al.] // Invest New Drugs. – 2011. – Vol.
29. – P. 126-130.114. Ostacolo, L. In vitro anticancer activity of docetaxel-loaded micelles based onpoly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrierproperties have a role? / L. Ostacolo, M. Marra, F. Ungaro [et al.] // Journal ofControlled Release. – 2010.
– Vol. 148. – P. 255-263.115. PDA Technical Report № 26. “Sterilizing Filtration of Liquids.” // J.Pharm.Sci. and Technol. – 1998. – 52 p.116. Pereira Rodrigues, E. Structure – activity relationships in a series ofsubstituted indolocarbazoles: topoisomerase I and protein kinase C ingibition andantitumoral and antimicrobial properties / E. Pereira Rodrigues, L. Belin, M.Sancelme [et al.] // J. Med.Chem. – 1996. – Vol.
39. – P. 4471-4477.117. Plaks, V. Photodynamic Therapy of Established Prostatic Adenocarcinomawith TOOKAD: A Biphasic Apparent Diffusion Coefficient Change as PotentialEarly MRI Response Marker / V. Plaks, N. Koudinova, U. Nevo et al. // Neoplasia.– 2004. – Vol. 6. – № 3. – P. 224-233.118. Plas, D.R. Akt-dependent transformation: there is more to growth than justsurviving / D.R. Plas, C.B. Thompson // Oncogene – 2005. – Vol. 24.
– P. 74357442.119. Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses EachPatients' Own Immune Cells. [Электронный ресурс] Режим доступа:http://clinicaltrials.gov/ct2/show/NCT00289341?term=DMSO&rank=27обращения: 25.10.13)(дата120. Safety of Active Immunotherapy in Subjects With Ovarian Cancer.[Электронный ресурс] Режим доступа:http://clinicaltrials.gov/ct2/show/NCT01456065?term=DMSO&rank=21обращения: 25.10.13)(дата121. Salioua, B. Development and in vitro evaluation of a novel lipid nanocapsuleformulation of etoposide / B.
Salioua, O. Thomasa, N. Lautrama [et al.] //European Journal of Pharmaceutical Sciences. – 2013. – Vol. 2. – P.172-180.130122.Sanche,L.Compositions comprising a radiosensitizer and ananti-cancer agent and methods of uses thereof / L. Sanche, G. Charest // заяв. пат.13/259,213 США. – 2010.123. Schwandt, A. Phase-II trial of rebeccamycin analog, a dual topoisomerase-Iand -II inhibitor, in relapsed "sensitive" small cell lung cancer / A. Schwandt, T.Mekhail, B. Halmos [et al.] // J Thorac Oncol. – 2012 – Vol.
7. – № 4. – P.751754.124. Senderowicz, A.M. Inhibitors of cyclin-dependent kinase modulators forcancer therapy / A.M. Senderowicz // Prog Drug Res. – 2005. – Vol. 63. – P. 183206.125. Siddique, H. Mixed matrix membranes for organic solvent nanofiltration / H.Siddique, E. Rundquist, Y. Bhole [et al.] // Journal of Membrane Science. – 2013.– Vol. 15. – P. 354-366.126. Sundaram, S. Method for qualifying microbial removal performance of 0.1micron rated filters. Part IV: Retention of hydrogenophaga pseudoflava (ATCC700892) and Ralstonia pickettii (ATCC 700591) by 0.2 and 0.22 micron ratedfilters / S.
Sundaram, M. Lewis, J. Eisenhuth [et al.] // J. Pharm. Sci. Techol. –2002. – Vol. 3. – P. 150-171.127. Talegaonkar, S. Microemulsions: a novel approach to enhanced drug delivery/ S. Talegaonkar, A. Azeem, F.J. Ahmad et al. // Recent Patents on Drug Delivery& Formulation. – 2008. – Vol.
2. – №. 3. – P. 238-257.128. Vaccine Therapy With or Without Imiquimod in Treating Patients Who HaveUndergone Surgery for Stage II, Stage III, or Stage IV Melanoma. [Электронныйресурс] Режим доступа:http://clinicaltrials.gov/ct2/show/NCT00118313?term=DMSO&rank=15обращения: 25.10.13)(дата129. Vancoillie, J. Continuous melt granulation: Effect of different binders upongranule and tablet properties / J. Vancoillie // Faculty of pharmaceutical sciences.Ghent University. – 2014 – 56 p.130.
Vyas, A. Cyclodextrin based novel drug delivery systems / A. Vyas, S. Saraf// J. Incl. Phenom. Macrocycl. Chem. – 2008. – Vol. 62. – P.23-42.131131. Wen, C. Crassicauline A/β - cyclodextrinhost–guestsystem:Preparation, characterization, inclusion mode, solubilization and stability / C. Wen,Y. Li-Juan, M.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
